We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Shrinking gracefully

16 November 2009 By Robert Cyran

The US drugs maker is offering its stockholders the chance to swap at a discount into shares of its publicly traded subsidiary Mead Johnson. That would improve Bristol s earnings per share which should come in handy with as much as 30% of its sales at risk as patents expire.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)